New York Vioxx suit
The state and city of New York file a joint lawsuit against Merck claiming company committed Medicaid fraud by concealing the drug's cardiovascular risks. The Sept. 17 complaint seeks damages and recovery of the millions of dollars the state spent on prescriptions for rofecoxib from its introduction in 1999 until its withdrawal in 2004. Merck says that it "acted within a week after one of its own studies suggested, for the first time, an increased relative risk with Vioxx compared to placebo." Merck is facing similar suits from attorneys general in six other states...
You may also be interested in...
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.